{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:09:47Z","timestamp":1790917787749,"version":"4.1.0"},"reference-count":43,"publisher":"American Association for Cancer Research (AACR)","issue":"19","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>NAD(P)H:quinone oxidoreductase 1 null (NQO1\u2212\/\u2212) mice exposed to 3 Gy of \u03b3-radiation showed an increase in neutrophils, bone marrow hypercellularity, and enlarged lymph nodes and spleen. The spleen showed disrupted follicular structure, loss of red pulp, and granulocyte and megakarocyte invasion. Blood and histologic analysis did not show any sign of infection in mice. These results suggested that exposure of NQO1\u2212\/\u2212 mice to \u03b3-radiation led to myeloproliferative disease. Radiation-induced myeloproliferative disease was observed in 74% of NQO1\u2212\/\u2212 mice as compared with none in wild-type (WT) mice. NQO1\u2212\/\u2212 mice exposed to \u03b3-radiation also showed lymphoma tissues (32%) and lung adenocarcinoma (84%). In contrast, only 11% WT mice showed lymphoma and none showed lung adenocarcinoma. Exposure of NQO1\u2212\/\u2212 mice to \u03b3-radiation resulted in reduced apoptosis in granulocytes and lack of induction of p53, p21, and Bax. NQO1\u2212\/\u2212 mice also showed increased expression of myeloid differentiation factors CCAAT\/enhancer binding protein \u03b1 (C\/EBP\u03b1) and Pu.1. Intriguingly, exposure of NQO1\u2212\/\u2212 mice to \u03b3-radiation failed to induce C\/EBP\u03b1 and Pu.1, as was observed in WT mice. These results suggest that decreased p53\/apoptosis and increased Pu.1 and C\/EBP\u03b1 led to myeloid hyperplasia in NQO1\u2212\/\u2212 mice. The lack of induction of apoptosis and differentiation contributed to radiation-induced myeloproliferative disease in NQO1\u2212\/\u2212 mice. [Cancer Res 2008;68(19):7915\u201322]<\/jats:p>","DOI":"10.1158\/0008-5472.can-08-0766","type":"journal-article","created":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T04:53:23Z","timestamp":1222836803000},"page":"7915-7922","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Disruption of NAD(P)H:Quinone Oxidoreductase 1 Gene in Mice Leads to Radiation-Induced Myeloproliferative Disease"],"prefix":"10.1158","volume":"68","author":[{"given":"Karim","family":"Iskander","sequence":"first","affiliation":[{"name":"1Department of Pharmacology, Baylor College of Medicine,"},{"name":"3Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto J.","family":"Barrios","sequence":"additional","affiliation":[{"name":"2Department of Pathology, Methodist Hospital, Houston, Texas; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K.","family":"Jaiswal","sequence":"additional","affiliation":[{"name":"1Department of Pharmacology, Baylor College of Medicine,"},{"name":"3Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2008,9,30]]},"reference":[{"key":"2022061700270828300_B1","doi-asserted-by":"crossref","unstructured":"Radjendirane V, Joseph P, Jaiswal AK. Gene expression of DT-diaphorase (NQO1) in cancer cells. In: Forman HJ, Cadenas E, editors. Oxidative stress and signal transduction. New York: Chapman & Hall; 1997. p. 441\u201375.","DOI":"10.1007\/978-1-4615-5981-8_18"},{"key":"2022061700270828300_B2","doi-asserted-by":"crossref","unstructured":"Riley RJ, Workman P. DT-diaphorase and cancer chemotherapy. Biochem Pharm\u20081992; 43: 1657\u201369.","DOI":"10.1016\/0006-2952(92)90694-E"},{"key":"2022061700270828300_B3","doi-asserted-by":"crossref","unstructured":"Lind C, Hochstein P, Ernster L. DT-diaphorase: properties, reaction mechanism, metabolic function. A progress report. In: King TE, Mason HS, Morrison M, editors. Oxidases and related redox systems. Oxford: Pergamon Press; 1982. p. 321\u201347.","DOI":"10.1016\/B978-0-08-024421-1.50020-3"},{"key":"2022061700270828300_B4","doi-asserted-by":"crossref","unstructured":"Jaiswal AK. Nrf2 signaling in coordinated activation of antioxidant gene expression. Free Radic Biol Med\u20082004; 36: 1199\u2013207.","DOI":"10.1016\/j.freeradbiomed.2004.02.074"},{"key":"2022061700270828300_B5","doi-asserted-by":"crossref","unstructured":"Jaiswal AK, Bell DW, Radjendirane V, Testa JR. Localization of human NQO1 gene to chromosome 16q22 and NQO2-6p25 and associated polymorphism. Pharmacogenetics\u20081999; 9: 413\u20138.","DOI":"10.1097\/00008571-199906000-00020"},{"key":"2022061700270828300_B6","unstructured":"Traver RD, Horikoshi T, Danenberg KD, et al. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res\u20081992; 52: 797\u2013802."},{"key":"2022061700270828300_B7","doi-asserted-by":"crossref","unstructured":"Siegel D, Anwar A, Winski SL, Kepa JK, Zolman KL, Ross D. Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1. Mol Pharmacol\u20082001; 59: 263\u20138.","DOI":"10.1124\/mol.59.2.263"},{"key":"2022061700270828300_B8","doi-asserted-by":"crossref","unstructured":"Siegel D, McGuinessess SM, Winski SL, Ross D. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics\u20081999; 9: 113\u201321.","DOI":"10.1097\/00008571-199902000-00015"},{"key":"2022061700270828300_B9","doi-asserted-by":"crossref","unstructured":"Kelsey KT, Ross D, Traver RD, et al. Ethnic variation in the prevalance of a common NAD(P)H:quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br J Cancer\u20081997; 76: 852\u20134.","DOI":"10.1038\/bjc.1997.474"},{"key":"2022061700270828300_B10","doi-asserted-by":"crossref","unstructured":"Rosvold EA, McGlynn KA, Lustbader ED, Buetow KH. Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics\u20081995; 5: 199\u2013206.","DOI":"10.1097\/00008571-199508000-00003"},{"key":"2022061700270828300_B11","doi-asserted-by":"crossref","unstructured":"Schulz WA, Krummeck A, Rosinger I, Schmitz-Drager BJ, Sies H. Predisposition towards urolithiasis associated with the NQO1 null-allele. Pharmacogenetics\u20081998; 8: 453\u20134.","DOI":"10.1097\/00008571-199810000-00011"},{"key":"2022061700270828300_B12","unstructured":"Weincke JK, Spitz MR, McMillan A, Kelsey KT. Lung Cancer in Mexican-Americans and African Americans is associated with the wild-type genotype of the NAD(P)H:quinone oxidoreductase polymorphism. Cancer Epidemiol Biomark Prev\u20081997; 6: 87\u201392."},{"key":"2022061700270828300_B13","unstructured":"Rothman N, Smith MT, Hayes RB, et al. Benzene poisoning, a risk factor for hematologic malignancy, is associated with NQO1 609 C\u2192T mutation and rapid fractional excretion of chlorzoxazone. Cancer Res\u20081997; 57: 2839\u201342."},{"key":"2022061700270828300_B14","doi-asserted-by":"crossref","unstructured":"Larson RA, Wang Y, Banerjee M, et al. Prevalence of the inactivating 609C\u2192T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood\u20081999; 94: 803\u20137.","DOI":"10.1182\/blood.V94.2.803.414k44_803_807"},{"key":"2022061700270828300_B15","doi-asserted-by":"crossref","unstructured":"Smith MT, Wang Y, Kane E, et al. Low NAD(P)H:quinone oxidoreductase1 activity is associated with increased risk of acute leukemia in adults. Blood\u20082001; 97: 1422\u20136.","DOI":"10.1182\/blood.V97.5.1422"},{"key":"2022061700270828300_B16","unstructured":"Wiemels JL, Pagnamenta A, Taylor GM, Eden OB, Alexander FE, Greaves MF. A lack of a functional NAD(P)H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. Cancer Res\u20081999; 59: 4095\u20139."},{"key":"2022061700270828300_B17","doi-asserted-by":"crossref","unstructured":"Smith MT, Wang Y, Skibola CF, et al. Low NAD(P)H:quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and children. Blood\u20082002; 100: 4590\u20133.","DOI":"10.1182\/blood-2001-12-0264"},{"key":"2022061700270828300_B18","doi-asserted-by":"crossref","unstructured":"Radjendirane V, Joseph P, Lee H, et al. Disruption of the DT diaphorase (NQO1) gene in mice leads to increased menadione toxicity. J Biol Chem\u20081998; 273: 7382\u20139.","DOI":"10.1074\/jbc.273.13.7382"},{"key":"2022061700270828300_B19","doi-asserted-by":"crossref","unstructured":"Gaikwad A, Long DJ II, Stringer JL, Jaiswal AK. In vivo role of NAD(P)H:quinone oxidoreductase 1 (NQO1) in the regulation of intracellular redox state and accumulation of abdominal adipose tissue. J Biol Chem\u20082001; 276: 22559\u201364.","DOI":"10.1074\/jbc.M101053200"},{"key":"2022061700270828300_B20","unstructured":"Long II DJ, Gaikwad A, Multani A, et al. Disruption of the NAD(P)H:quinone oxidoreductase 1 (NQO1) gene in mice causes myelogenous hyperplasia. Cancer Res\u20082002; 62: 3030\u20136."},{"key":"2022061700270828300_B21","unstructured":"Bauer AK, Faiola B, Abernethy DJ, et al. Genetic susceptibility to benzene-induced toxicity: role of NADPH:quinone oxidoreductase-1. Cancer Res\u20082003; 63: 929\u201335."},{"key":"2022061700270828300_B22","unstructured":"LongII DJ, Waikel RL, Wang X, Perlaky L, Roop DR, Jaiswal AK. NAD(P)H:quinone oxidoreductase 1 deficiency increases susceptibility to benzo(a)pyrene-induced mouse skin carcinogenesis. Cancer Res\u20082000; 60: 5913\u20135."},{"key":"2022061700270828300_B23","doi-asserted-by":"crossref","unstructured":"Long DJ, Waikel RL, Wang XJ, Roop DR, Jaiswal AK. NAD(P)H:quinone oxidoreductase 1 deficiency and increased susceptibility to 7,12-dimethylbenz[a]-anthracene-induced carcinogenesis in mouse skin. J Natl Cancer Inst\u20082001; 93: 1166\u201370.","DOI":"10.1093\/jnci\/93.15.1166"},{"key":"2022061700270828300_B24","doi-asserted-by":"crossref","unstructured":"Iskander K, Paquet M, Brayton C, Jaiswal AK. Deficiency of NRH:quinone oxidoreductase 2 increases susceptibility to 7,12-dimethybenz(a)anthracene and benzo(a)pyrene-induced skin carcinogenesis. Cancer Res\u20082004; 64: 5925\u20138.","DOI":"10.1158\/0008-5472.CAN-04-0763"},{"key":"2022061700270828300_B25","doi-asserted-by":"crossref","unstructured":"Iskander K, Gaikwad A, Paquet M et al. Lower induction of p53 and decreased apoptosis in NQO1-null mice leads to increased sensitivity of chemical-induced skin carcinogenesis. Cancer Res\u20082005; 65: 2054\u20138.","DOI":"10.1158\/0008-5472.CAN-04-3157"},{"key":"2022061700270828300_B26","unstructured":"Pathak S. Chromosome banding techniques. J Reprod Med\u20081976; 17: 25\u20138."},{"key":"2022061700270828300_B27","doi-asserted-by":"crossref","unstructured":"Sawyer JR, Moore MM, Hozier JC. High resolution G-banding chromosomes of the mouse. Chromosoma\u20081987; 95: 350\u20138.","DOI":"10.1007\/BF00293182"},{"key":"2022061700270828300_B28","doi-asserted-by":"crossref","unstructured":"Kogan SC, Ward JM, Anver MR, et al. Hematopathology subcommittee of the mouse models of human cancers consotium. Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood\u20082002; 100: 238\u201345.","DOI":"10.1182\/blood.V100.1.238"},{"key":"2022061700270828300_B29","doi-asserted-by":"crossref","unstructured":"Gong X, Kole L, Iskander K, Jaiswal AK. NRH:quinone oxidoreductase 2 and NAD(P)H:quinone oxidoreductase 1 protect tumor suppressor p53 against 20S proteasomal degradation leading to stabilization and activation of p53. Cancer Res\u20082007; 67: 5380\u20138.","DOI":"10.1158\/0008-5472.CAN-07-0323"},{"key":"2022061700270828300_B30","doi-asserted-by":"crossref","unstructured":"Pietsch EC, Humbey O, Murphy ME. Polymorphism in the p53 pathway. Oncogene\u20082006; 25: 1602\u201311.","DOI":"10.1038\/sj.onc.1209367"},{"key":"2022061700270828300_B31","doi-asserted-by":"crossref","unstructured":"Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein \u03b1-deficient mice. Proc Natl Acad Sci U S A\u20081997; 94: 569\u201374.","DOI":"10.1073\/pnas.94.2.569"},{"key":"2022061700270828300_B32","doi-asserted-by":"crossref","unstructured":"Anderson KL, Smith KA, Conners K, McKercher SR, Maki RA, Torbett BE. Myeloid development is selectively disrupted in Pu.1 null mice. Blood\u20081998; 91: 3702\u201310.","DOI":"10.1182\/blood.V91.10.3702"},{"key":"2022061700270828300_B33","doi-asserted-by":"crossref","unstructured":"Rosenbauer F, Wagner K, Kutok JL, et al. Acute myeloid leukemia induced by graded reduction of a lineage-specific factor, PU.1. Nat Genet\u20082004; 36: 624\u201330.","DOI":"10.1038\/ng1361"},{"key":"2022061700270828300_B34","doi-asserted-by":"crossref","unstructured":"Miranda MB, Johnson DE. Signal transduction pathways that contribute to myeloid differentiation. Leukemia\u20082007; 21: 1363\u201377.","DOI":"10.1038\/sj.leu.2404690"},{"key":"2022061700270828300_B35","doi-asserted-by":"crossref","unstructured":"Kaeferstein A, Krug U, Tiesmeier J, et al. The emergence of a C\/EBP\u03b1 mutation in the clonal evolution of MDS towards secondary AML. Leukemia\u20082003; 17: 343\u20139.","DOI":"10.1038\/sj.leu.2402805"},{"key":"2022061700270828300_B36","doi-asserted-by":"crossref","unstructured":"Dekoter RP, Kamath MB, Houston IB. Analysis of concentration-dependent functions of PU.1 in hematopoiesis using mouse models. Blood Cells Mol Dis\u20082007; 39: 316\u201320.","DOI":"10.1016\/j.bcmd.2007.06.004"},{"key":"2022061700270828300_B37","doi-asserted-by":"crossref","unstructured":"Asher G, Loten J, Sachs L, et al. Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1. Proc Natl Acad Sci U S A\u20082002; 99: 13125\u201330.","DOI":"10.1073\/pnas.202480499"},{"key":"2022061700270828300_B38","doi-asserted-by":"crossref","unstructured":"Jawad M, Cole C, Zanker A, Priscilla L, Fitch S, Plumb M. Evidence for clustered tumour suppressor gene loci on mouse chromosome 2 and 4 in radiation-induced acute myeloid leukemia. Int J Radiat Biol\u20082006; 82: 383\u201391.","DOI":"10.1080\/09553000600784161"},{"key":"2022061700270828300_B39","doi-asserted-by":"crossref","unstructured":"Rithidech K, Dunn JJ, Roe BA, Gordon CR, Cronkite EP. Evidence for two commonly deleted regions on mouse chromosome 2 in g ray-induced acute myeloid leukemic cells. Exp Hematol\u20082002; 30: 564\u201370.","DOI":"10.1016\/S0301-472X(02)00799-3"},{"key":"2022061700270828300_B40","doi-asserted-by":"crossref","unstructured":"Zimonjic DR, Pollock JL, Westervelt P, Popescu NC, Ley TJ. Acquired, nonrandom chromosomal abnormalities associated with the development of acute promyelocytic leukemia in transgenic mice. Proc Natl Acad Sci U S A\u20082000; 97: 13306\u201311.","DOI":"10.1073\/pnas.97.24.13306"},{"key":"2022061700270828300_B41","doi-asserted-by":"crossref","unstructured":"Walter MJ, Park JS, Ries RE, et al. Reduced Pu.1 expression causes myeloid progenitor expansion and increased leukemia penetrance in mice expressing PML-RARa. Proc Natl Acad Sci U S A\u20082005; 102: 12513\u20138.","DOI":"10.1073\/pnas.0504247102"},{"key":"2022061700270828300_B42","doi-asserted-by":"crossref","unstructured":"Joslin JM, Fernald AA, Tennant TR, et al. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood\u20082007; 110: 719\u201326.","DOI":"10.1182\/blood-2007-01-068809"},{"key":"2022061700270828300_B43","doi-asserted-by":"crossref","unstructured":"Lezon-Geyda K, Najfeld V, Johnson EM. Deletions of PURA, at 5q31, and PURB, at 7p13, in myelodysplastic syndrome and progression to acute myelogenous leukemia. Leukemia\u20082001; 15: 954\u201362.","DOI":"10.1038\/sj.leu.2402108"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/19\/7915\/2597658\/7915.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/19\/7915\/2597658\/7915.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T04:46:20Z","timestamp":1655441180000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/68\/19\/7915\/541670\/Disruption-of-NAD-P-H-Quinone-Oxidoreductase-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,30]]},"references-count":43,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2008,9,30]]},"published-print":{"date-parts":[[2008,10,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-08-0766","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9,30]]}}}